The Regulation of Hedge Funds
A Global Perspective
Compares the regulation of hedge funds in United States, Europe, the UK, and off-shore jurisdictions in the aftermath of the financial crisis
Critically evaluates the Dodd-Frank Act in United States with the Alternative Investment Funds Managers Directive in Europe
Analyses the effect of Brexit on the legislation in UK and the application of the directive and the distribution of financial products in Continental Europesee more benefits
Buy this book
Immediate eBook download after purchase Hardcover $139.99
Institutional customers should get in touch with their account manager
This book analyses elements of international finance, comparing the regulation of hedge funds in United States, Europe, the UK, and off-shore jurisdictions in the aftermath of the financial crisis. It critically compares the Dodd- Frank Act in US with the Alternative Investment Funds Managers Directive in Europe. M
Jersey is witnessing a spike in the inflow of private equity fund managers establishing a physical presence on the island. A number of household name fund managers across all asset classes now call Jersey home, with others in advanced stages of planning to follow them into Jersey. What are the principal drivers of this trend?
A
Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient: 1. Obtains access to the information in a personal capacity; 2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services; 3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body; 4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost
Wed, 23rd Dec 2020 19:50
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Wednesday and not separately reported by Alliance News:
Polarean Imaging PLC - medical imaging products developer - Says US Food & Drug Administration approves company s new drug application. FDA acceptance for the filing of Polarean s NDA represents another important step forward for the Company s platform. If approved, Polarean s drug-device technology could provide a new diagnostic option for patients with pulmonary disease, Chief Executive Officer Richard Hullihen says. Polarean adds that Chief Operating Officer Ken West plans to retire as employee of company but to stay involved as a consultant before transitioning to non-executive role.
(the Company ) Legal Entity Identifier : 549300OHW8R1C2WBYK02 Results The year to 30th September 2020 was a volatile one for global equity markets and a negative one for investors in India, as indicated by our benchmark index, the MSCI India Index (in sterling terms), which returned -4.2%. Unfortunately, the Company performed poorly, both in absolute and relative terms, with a total return on net assets of -16.2% over the year. The share price fell sharply, from 744.0p to 571.5p, and the discount widened out from 9.3% at the beginning of the year to 16.8% at the year end, resulting in a total return to shareholders of -23.2%.